Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01933672 · ClinicalTrials.gov registry record · Phase 1
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01933672 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 33 participants.
The verdict
NCT01933672, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes
Interventions
- DRUG PF-04937319 once-daily
- DRUG PF-04937319 split-dose
- DRUG Sitagliptin once-daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01933672
The ClinicalTrials.gov registry entry for NCT01933672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-04937319 once-daily is the first listed.
NCT01933672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01933672 about?
NCT01933672 is a clinical study titled "Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes". Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes
What is the current status of trial NCT01933672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2013-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01933672?
The interventions under investigation include: PF-04937319 once-daily (DRUG), PF-04937319 split-dose (DRUG), Sitagliptin once-daily (DRUG).
Who is sponsoring clinical trial NCT01933672?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.